|Bid||2.7100 x 800|
|Ask||2.7500 x 900|
|Day's Range||2.2060 - 2.8800|
|52 Week Range||1.2300 - 22.3900|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Aug 01, 2018|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for HXLearn more
Xiaobai Maimai Inc. (NASDAQ: HX) ("Xiaobai Maimai" or the "Company"), today announced that it held the 2021 annual general meeting of shareholders (the "AGM") at the Meeting Room, Futian Shangri-La, 4088 Yi Tian Road, Futian District, Shenzhen 518408, People's Republic of China, at 10:00 a.m. (Beijing Time) on December 3, 2021. At the AGM, holders of 71,057,650 ordinary shares (including ordinary shares represented by the Company's American Depositary Shares), out of the 71,478,550 ordinary shar
Xiaobai Maimai Inc. (NASDAQ: HX) ("Xiaobai Maimai," the "Company," or "we"), today announced the appointment of Dr. Yingxian Liu as the medical consultant to the Company. Dr. Liu will work closely with management to develop the Company's cancer therapy and radiation oncology business by the Company's wholly-owned subsidiary, We Health Limited.
Xiaobai Maimai Inc. (NASDAQ: HX) ("Xiaobai Maimai", the "Company", or "we"), a social e-commerce platform in China, today announced that it plans to enter the radiation oncology services market in the U.S.